创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology iHuPDX Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-09-03 15:42
  • Views:

(Summary description)In the biomedical field, innovation is a key driver for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. iHuPDX platform not only demonstrates InnoModels BioTech's profound strength in the field of personalized medicine, but also provides new hopes and possibilities for tumor treatment. The iHuPDX platform not only demonstrates the profound strength of Thermo Scientific in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.

InnoModels Biotechnology iHuPDX Platform

(Summary description)In the biomedical field, innovation is a key driver for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. iHuPDX platform not only demonstrates InnoModels BioTech's profound strength in the field of personalized medicine, but also provides new hopes and possibilities for tumor treatment. The iHuPDX platform not only demonstrates the profound strength of Thermo Scientific in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-09-03 15:42
  • Views:
Information

In the biomedical field, innovation is a key driver for technological advancement and clinical application. With its iHuPDX (Individualized Human Patient-Derived Xenograft) platform, InnoModels Biotechnology (Beijing) Co., Ltd. is bringing unprecedented changes to cancer research and treatment. iHuPDX platform not only demonstrates InnoModels BioTech's profound strength in the field of personalized medicine, but also provides new hopes and possibilities for tumor treatment. The iHuPDX platform not only demonstrates the profound strength of Thermo Scientific in the field of personalized medicine, but also provides new hope and possibilities for tumor treatment.
Background and Technical Principle of iHuPDX Platform
The iHuPDX platform is a xenotransplantation technology based on patients' individual tumor cells, aiming to establish a more realistic and individualized cancer model. The technology collects cancer tissue samples from patients and transplants them into animals such as mice to form individualized transplanted tumors. This highly individualized disease model can more accurately simulate the biological characteristics of a patient's tumor, such as growth, metastasis and drug response, providing strong support for precision medicine.
Advantages and applications of iHuPDX platform
1. Accurately simulate patients' tumor characteristics
Traditional tumor models are often based on standardized cell lines or tissue samples, which cannot fully reflect the uniqueness of patient tumors. The iHuPDX platform, on the other hand, is derived directly from the patient's tumor cells, and is therefore able to more accurately simulate the growth and metastasis of the patient's tumor. This individualized disease model not only helps doctors to understand the patient's tumor characteristics more comprehensively, but also provides an important basis for the development of personalized treatment plans.
2. Drug response prediction
Due to the high degree of similarity between the iHuPDX platform and the patient's tumor, researchers can test the response of different drugs to a specific patient's tumor on the model, thus predicting the drug's efficacy and possible side effects in the patient. This predictive capability enables physicians to select the most appropriate drug combination and dosage for a patient before treatment, increasing the success rate of treatment and reducing unnecessary risks.
3. Broad Application Areas
The iHuPDX platform has a wide range of applications in the fields of cancer research, drug development, tumor biology research, and tumor immunity-related research. It not only provides researchers with experimental animal models that are closer to the clinic, but also promotes the development of new drug development and translational medicine. Through this platform, researchers are able to explore more deeply the differences in tumor heterogeneity among different patients, reveal the diversity of cancers, and provide important information for the development of individualized treatment strategies.

 


Strength and Future Prospects of InnoModels Biotechnology
Founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion, and the Institute of Immunology of Shanghai Jiaotong University, InnoModels Biotechnology (Beijing) Ltd. is endowed with rich scientific research resources and strong technical support. With a stable domestic platform of humanized mouse model of immune system (HIS) and human tumor xenograft platform (PDX), the company is committed to providing the most clinically referenced preclinical research support for oncology and tumor immunotherapy innovators.
InnoModels Biotechnology is confident in the future of the iHuPDX platform. With the deepening of biomedical research and continuous technological innovation, the iHuPDX platform is expected to play a more important role in the field of personalized medicine. In the future, we can expect to see more research results and application scenarios related to the iHuPDX platform, which will bring hope and gospel to more patients.
Conclusion
With its unique advantages and wide range of application areas, iHuPDX platform of InnoModels Biotechnology is leading the new trend of personalized medicine. By providing highly individualized tumor models for medical research and drug development, the iHuPDX platform brings new possibilities for precision cancer treatment. InnoModels Biotechnology will continue to devote itself to promoting the development of this technology, providing patients with more effective treatment options, and contributing to the continuous progress of the biomedical field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司